Edoxaban for the long-term treatment of venous thromboembolism: Rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 7, 2013, Pages 1287-1294

  Raskob, G ^a   Buller H ^b   Prins, M ^c   Segers, A ^d   Shi, M ^e   Schwocho, L ^e   Van Kranen, R ^f   Mercuri, M ^e  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Academic Research Organization   (Netherlands)

^e DAIICHI SANKYO INC   (United States)

^f DAIICHI SANKYO CO   (Japan)

Author keywords

Anticoagulant drugs; Clinical trial; Edoxaban; Venous thromboembolism

Indexed keywords

EDOXABAN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; LONG TERM CARE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANT DRUGS; CLINICAL TRIAL; EDOXABAN; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FACTOR XA; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREDICTIVE VALUE OF TESTS; PYRIDINES; RECURRENCE; RESEARCH DESIGN; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84880397241     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12230     Document Type: Article

References (29)

1. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR, American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl. 2): e419S-94S.
2. Cardiovascular Disease Educational and Research Trust, Cyprus Cardiovascular Disease Educational and Research Trust, European Venous Forum, International Surgical Thrombosis Forum, International Union of Angiology, Union Internationale de Phlébologie. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006; 25: 101-61.
3. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl. 2): e44S-88S.
4. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S, ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-37.
5. Weitz JI, Eikelboom JW, Samama MM, American College of Chest Physicians. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl. 2): e120S-51S.
6. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50: 743-53.
7. Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Absolute bioavailability of edoxaban in healthy subjects. AAPS J 2011; 13(Suppl. 2). Abstract T2362.
8. Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomized double-blind dose-response study. Thromb Haemost 2010; 104: 642-9.
9. Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010; 8: 2458-68.
10. Fuji T, Fujita S, Tachibana S, Kawai Y, Koretsune Y, Yamashita T, Nakamura M. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial. Blood (ASH Annual Meeting Abstracts) 2010; 116: 3320 [abstract].
11. Fuji T, Wang C-J, Fujita S, Tachibana S, Kawai Y, Koretsune Y, Yamashita T, Nakamura M. Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Pathophysiol Haemost Thromb 2010; 37: A20 [abstract OC297].
12. Lixiana [Package Insert]. Tokyo, Japan: Daiichi Sankyo Co., Ltd, 2011.
13. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104: 633-41.
14. Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, Patel I, Bocanegra TS, Antman EM, Giugliano RP, Kunitada S, Dornseif B, Shi M, Tachibana M, Zhou S, Rohatagi S. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012; 107: 925-34.
15. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-702.
16. van Gogh Investigators, Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-104.
17. van Gogh Investigators, Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357: 1105-12.
18. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9.
19. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52.
20. Schulman S, Kearon C, Kakkar AK, Schellong SM, Eriksson H, Baanstra D, Kvamme A, Friedman J, Henry E, Mismetti P, Goldhaber SZ. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-18.
21. Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE, Cassiopea Investigators. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012; 379: 123-9.
22. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.
23. EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97.
24. Büller HR, Halperin JL, Bounameaux H, Prins M. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. J Thromb Haemost 2008; 6: 227-9.
25. Sackett DL. Bias in analytic research. J Chronic Dis 1979; 32: 51-63.
26. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-81.
27. Deitelzweig SB, Lin J, Kreilick C, Hussein M, Battleman D. Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther 2010; 27: 623-33.
28. Willey VJ, Bullano MF, Hauch O, Reynolds M, Wygant G, Hoffman L, Maxwell G, Spyropoulos AC. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 2004; 26: 1149-59.
29. Sackett DL. The competing objectives of randomized trials. N Engl J Med 1980; 303: 1059-60.